Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients

被引：0
|
作者：
Desmedt, C.
Andre, F.
Azambuja, E.
Haibe-Kains, B.
Larsimont, D.
D'Hondt, V.
Di Leo, A.
Piccart, M.
Pusztai, L.
Sotiriou, C.
机构：
[1] Jules Bordet Inst, Brussels, Belgium
[2] Inst Gustave Roussy, Villejuif, France
[3] Prato Hosp, Prato, Italy
[4] MD Anderson, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10564
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Gene expression profiling to predict neoadjuvant toremifene activity in estrogen receptor-positive (ER+) breast cancers.
    Daidone, MG
    Cappelletti, V
    Bajetta, E
    Celio, L
    De Cecco, L
    Fabbri, A
    Gariboldi, M
    Greco, M
    Lusa, L
    Reid, JF
    Pierotti, MA
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S47 - S47
  • [42] ESTROGEN RECEPTOR AS A NEGATIVE PREDICTOR OF COMPLETE PATHOLOGICAL RESPONSE IN HER2 POSITIVE LOCALLY ADVANCED BREAST CANCER
    Canario, Rita
    Cruz, Jorge
    Casalta-Lopes, Joao
    Goncalves, Bruno
    Mariano, Monica
    Broco, Sofia
    Pais, Ana
    Pazos, Isabel
    Carvalho, Teresa
    Pego, Antonio
    Madeira, Pedro
    Sousa, Gabriela
    Gervasio, Helena
    BREAST, 2015, 24 : S46 - S46
  • [43] Vitamin D induces expression of estrogen receptor and restores endocrine therapy response in estrogen receptor-negative breast cancer
    Santos, N.
    Diaz, L.
    Ordaz, D.
    Garcia, J.
    Barrera, D.
    Avila, E.
    Halhali, A.
    Medina, H.
    Camacho, J.
    Larrea, F.
    Garcia, R.
    CANCER RESEARCH, 2012, 72
  • [44] The role of glucocorticoid receptor (GR) expression in predicting pathological complete response (pCR) to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC)
    Saha, P.
    Turk, A.
    Lurain, K.
    Baker, G.
    Conzen, S.
    Nanda, R.
    CANCER RESEARCH, 2016, 76
  • [45] Bcl2 Expression Predicts Clinical Outcome to Adjuvant Hormone Therapy and Response to Anthracycline-based Chemotherapy in ER+HER2-Breast Cancer
    Abdel-Fatah, T. M.
    Barros, F.
    Green, A.
    Dickinson, P.
    Moseley, P.
    Reis-Filho, J. S.
    Ian, O. E.
    Chan, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S382 - S383
  • [46] Endocrine therapy resistance can be associated with high estrogen receptor α (ERα) expression and reduced ERα phosphorylation in breast cancer models
    Kuske, Barbara
    Naughton, Catherine
    Moore, Kate
    MacLeod, Kenneth G.
    Miller, William R.
    Clarke, Robert
    Langdon, Simon P.
    Cameron, David A.
    ENDOCRINE-RELATED CANCER, 2006, 13 (04) : 1121 - 1133
  • [47] Clinical Outcomes and Predictors of Pathological Response in Triple Negative Breast Cancer Patients Receiving Anthracycline/Taxane-Based Neoadjuvant Therapy
    Ciftci, Mehmet Sabri
    Ucaner, Burak
    Buldanli, Mehmet Zeki
    Hancerliogullari, Oguz
    Kaymak, Sahin
    Celik, Ertugrul
    INDIAN JOURNAL OF SURGERY, 2025,
  • [48] Role of progesterone receptor status (PR) as predictive factor of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients (pts)
    Perez Garcia, J. M., Sr.
    Saura, C.
    Munoz, E.
    Sanchez-Olle, G.
    Gomez, P.
    Peg, V.
    Sabadell, D.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
    de Freitas, A. J. A.
    Nunes, C. R.
    Causin, R. L.
    Calfa, S.
    de Oliveira, M. A.
    de Padua Souza, C.
    Marques, M. M. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S202 - S202
  • [50] Gene signature predicts pathological complete response in triple negative breast cancer patients: NACATRINE trial
    Freitas, Ana J.
    Nunes, Caroline R.
    Causin, Rhafaela L.
    Santana, Iara V.
    Oliveira, Marco A.
    Calfa, Stephanie
    Souza, Cristiano P.
    Marques, Marcia M.
    CANCER RESEARCH, 2023, 83 (07)
12345